Cargando…

A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study

For populations with a high risk of nasopharyngeal carcinoma (NPC) in Guangdong province in southern China, mass screening is the first choice to prevent death from NPC. To improve the performance of NPC screening, we used a combination based on the IgA antibody against the Epstein-Barr virus (EBV)...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Dongping, Fu, Meiqin, Chen, Yingjie, Liu, Qing, Xiao, Lin, Zhang, Xin, Li, Zhongxiao, Li, Haitao, He, Yongyi, Chen, Yongxing, Chen, Jieying, Hu, Jin, Huang, Yanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666820/
https://www.ncbi.nlm.nih.gov/pubmed/33240616
http://dx.doi.org/10.7717/peerj.10254
_version_ 1783610207009505280
author Rao, Dongping
Fu, Meiqin
Chen, Yingjie
Liu, Qing
Xiao, Lin
Zhang, Xin
Li, Zhongxiao
Li, Haitao
He, Yongyi
Chen, Yongxing
Chen, Jieying
Hu, Jin
Huang, Yanming
author_facet Rao, Dongping
Fu, Meiqin
Chen, Yingjie
Liu, Qing
Xiao, Lin
Zhang, Xin
Li, Zhongxiao
Li, Haitao
He, Yongyi
Chen, Yongxing
Chen, Jieying
Hu, Jin
Huang, Yanming
author_sort Rao, Dongping
collection PubMed
description For populations with a high risk of nasopharyngeal carcinoma (NPC) in Guangdong province in southern China, mass screening is the first choice to prevent death from NPC. To improve the performance of NPC screening, we used a combination based on the IgA antibody against the Epstein-Barr virus (EBV) capsid antigen (VCA-IgA) and the IgA antibody against Epstein-Barr virus nuclear antigen 1 (EBNA1-IgA) to NPC screening by enzyme-linked immunosorbent assay (ELISA). A multiplication model was applied to measure the level of the combination. We evaluated the NPC screening effect of the markers.A case-control study was performed to assess the NPC screening effect of the markers. A total of 10,894 serum specimens were collected, including 554 samples from NPC patients and 10,340 samples from healthy controls. In the training stage, 640 subjects were randomly selected, including 320 NPC cases and 320 healthy controls. In the verification stage, 10,254 subjects were used to verify the NPC screening effect of the combination. Receiver operating characteristic (ROC) analysis was performed. In the verification stage, the combination achieved an sensitivity of 91.45%, a specificity of 93.45%, and an area under the ROC curve (AUC) of 0.978 (95% CI [0.968–0.987]). Compared with VCA-IgA and EBNA1-IgA individually, the combination had an improved screening performance. A probability (PROB) calculated by logistic regression model based on VCA-IgA and EBNA1-IgA was applied to NPC screening by ELISA in China. The AUC of the combination was a little bit larger than the PROB. There was a slight increase (3.13%) in the sensitivity of the combination compared to the sensitivity of the PROB, while the specificity was lower for the combination (92.50%) than for the PROB (95.94%). We successfully applied a combination of two ELISA tests based on VCA-IgA and EBNA1-IgA for NPC screening by using a multiplication model. The results suggested that the combination was effective and can be an option for NPC screening.
format Online
Article
Text
id pubmed-7666820
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-76668202020-11-24 A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study Rao, Dongping Fu, Meiqin Chen, Yingjie Liu, Qing Xiao, Lin Zhang, Xin Li, Zhongxiao Li, Haitao He, Yongyi Chen, Yongxing Chen, Jieying Hu, Jin Huang, Yanming PeerJ Epidemiology For populations with a high risk of nasopharyngeal carcinoma (NPC) in Guangdong province in southern China, mass screening is the first choice to prevent death from NPC. To improve the performance of NPC screening, we used a combination based on the IgA antibody against the Epstein-Barr virus (EBV) capsid antigen (VCA-IgA) and the IgA antibody against Epstein-Barr virus nuclear antigen 1 (EBNA1-IgA) to NPC screening by enzyme-linked immunosorbent assay (ELISA). A multiplication model was applied to measure the level of the combination. We evaluated the NPC screening effect of the markers.A case-control study was performed to assess the NPC screening effect of the markers. A total of 10,894 serum specimens were collected, including 554 samples from NPC patients and 10,340 samples from healthy controls. In the training stage, 640 subjects were randomly selected, including 320 NPC cases and 320 healthy controls. In the verification stage, 10,254 subjects were used to verify the NPC screening effect of the combination. Receiver operating characteristic (ROC) analysis was performed. In the verification stage, the combination achieved an sensitivity of 91.45%, a specificity of 93.45%, and an area under the ROC curve (AUC) of 0.978 (95% CI [0.968–0.987]). Compared with VCA-IgA and EBNA1-IgA individually, the combination had an improved screening performance. A probability (PROB) calculated by logistic regression model based on VCA-IgA and EBNA1-IgA was applied to NPC screening by ELISA in China. The AUC of the combination was a little bit larger than the PROB. There was a slight increase (3.13%) in the sensitivity of the combination compared to the sensitivity of the PROB, while the specificity was lower for the combination (92.50%) than for the PROB (95.94%). We successfully applied a combination of two ELISA tests based on VCA-IgA and EBNA1-IgA for NPC screening by using a multiplication model. The results suggested that the combination was effective and can be an option for NPC screening. PeerJ Inc. 2020-11-12 /pmc/articles/PMC7666820/ /pubmed/33240616 http://dx.doi.org/10.7717/peerj.10254 Text en ©2020 Rao et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Epidemiology
Rao, Dongping
Fu, Meiqin
Chen, Yingjie
Liu, Qing
Xiao, Lin
Zhang, Xin
Li, Zhongxiao
Li, Haitao
He, Yongyi
Chen, Yongxing
Chen, Jieying
Hu, Jin
Huang, Yanming
A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study
title A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study
title_full A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study
title_fullStr A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study
title_full_unstemmed A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study
title_short A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study
title_sort combination of two elisa tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666820/
https://www.ncbi.nlm.nih.gov/pubmed/33240616
http://dx.doi.org/10.7717/peerj.10254
work_keys_str_mv AT raodongping acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT fumeiqin acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT chenyingjie acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT liuqing acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT xiaolin acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT zhangxin acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT lizhongxiao acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT lihaitao acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT heyongyi acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT chenyongxing acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT chenjieying acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT hujin acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT huangyanming acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT raodongping combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT fumeiqin combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT chenyingjie combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT liuqing combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT xiaolin combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT zhangxin combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT lizhongxiao combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT lihaitao combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT heyongyi combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT chenyongxing combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT chenjieying combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT hujin combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy
AT huangyanming combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy